Press Releases

MIB Agents Awards $200,000 in Grants to Colorado-based Researchers Studying Pediatric Osteosarcoma

MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors, and researchers, recently presented $100,000 each to Michael Leibowitz, MD, PhD from the University of Colorado Cancer Center and Dr. Daniel Regan, DVM, PhD, DACVP from the Flint Animal Cancer Center at Colorado State University, totaling $200,000 in research funds to move rare bone cancer research forward. Christina Ip-Toma, MIB Agents’ Director of Scientific Programs, presented the award to Dr. Leibowitz on February 8 and Dr. Regan on February 9.

Verana Health Announces Release of Qdata Module for Non-Muscle Invasive Bladder Cancer RWE Analysis

Second Urology Qdata Module to Provide Real-World Evidence from more than 50,000 De-identified Patients in the American Urological Association’s (AUA) Quality Registry (AQUA)

Biopharma PEG Supplies Multi-arm PEG Derivatives Crosslinked Into Hydrogels

Huateng Pharma Supplies Tetrahydrocurcumin With Large Scale

About Huateng Pharma Huateng Pharma is a global provider in contract development and manufacturing for pharmaceutical intermediates. With our focus on operational excellence, and the integration of manufacturing operations with EHS, quality assurance, quality control, regulatory, supply chain management and project management, we can manufacture, scale-up and supply high-quality intermediates and APIs from our China facility. We have established a 5000 square meters R&D center and have our own manufacturing site covering 34,000 square meters. Contact us Hunan Huateng Pharmaceutical Co. Ltd. Address: Lugu Business Plaza E1, Yuelu District, Changsha City, Hunan Province, China Manufacturing Base: Tongguan Kiln, Wangcheng district, Changsha, Hunan, China Email: sales@huatengusa.com Website: https://us.huatengsci.com Zip code: 410205 Telephone: +86 731 89916275 Fax: +86 0731-82251112-818

RTsafe announces first use of its PseudoPatient patient-specific quality assurance process by Fundación Instituto Valenciano de Oncología (IVO)

RTsafe has announced that Spain’s Fundación Instituto Valenciano de Oncología has conducted its first simulated therapy for brain metastases using RTsafe’s patient-specific quality assurance process, PseudoPatient.

BSI LIFE SCIENCES AND LEDGER RUN PARTNER TO STREAMLINE CLINICAL BUSINESS OPERATIONS

BSI Life Sciences specializes in state-of-the-art software for life sciences (CTMS, eTMF and more) and Ledger Run, Inc., an innovative technology company focused on optimizing clinical operations in the areas of site budgeting and payments, announced their partnership today. Through the partnership, BSI Life Sciences’ Clinical Trial Management software BSI CTMS™ and Ledger Run’s unique ClinRun™ platform will streamline and enhance clinical operation budgeting and payment processes with an intelligent approach and seamless integration.

BOC Sciences Established Large-Scale Fermentation Tanks of Different Volumes

Amerigo Scientific Releases Optimal ZediXclusive TG6-ab ELISA (IgA) Kits to Detect TG6-Autoantibodies in Human Sera

Amerigo Scientific released ZediXclusive TG6-ab ELISA Kits (IgA), optimized based on ZediXplore TG6-ELISA Kits (IgA) to support celiac disease-related studies.

Dolomite Bio announces re brand to Do Bio

Dolomite Bio has re-branded with a new website, a new name, and a new focus.

Quotient Sciences Expands Formulation Development Capabilities To Further Accelerate Drug Development Timelines

Company increases laboratory capacity to meet customer demand for fully integrated drug development capabilities

NDA Group Names New Chief Financial Officer to Lead Financial Strategy and Growth

NDA Group announces the appointment of Erik Bech-Jansen as the new Chief Financial Officer.

BOC Sciences Live Webinar on Sensitive Nucleic Acids: Applications and Chemical Synthesis

Professor Shiyue Fang from the Department of Chemistry, Michigan Technological University, accepted BOC Sciences' invitation to present his insightful ideas about sensitive nucleic acid applications and chemical synthesis.

BOC Sciences January 2023 Promo: An Economical (Bio)chemical Source for New Year Projects

As the new year approaches, BOC Sciences' January promotion is bang on time, as usual, to thank all regular customers for the year-round support and to welcome new partners to join.

Contract Research Organizations Gain Competitive Edge with Oracle Cloud Oracle

While increased investment in pharmaceutical research and development is creating more opportunities for Contract Research Organizations (CROs), many are struggling to keep pace with competitive pressures, changing market requirements, and a lack of skilled talent.  To help CROs meet these challenges, Oracle introduced its CRO Growth Initiative in August 2022. The global program offers CROs no-obligation access to Oracle Clinical One, a leading eClinical platform, for non-production purposes. Through the program, CROs can evaluate, familiarize, train, and enable their users with the technology and demonstrate the power of Clinical One to potential sponsors. Already, hundreds of CRO professionals have taken advantage of the program’s accelerator that provides go-to-market benefits, technical enablers, and incentives all constructed to help them to get trials up and running faster.

Thermo Fisher Scientific Collaborates to Introduce Fully Automated Cell Line Automation Platform

Thermo Fisher Scientific and Celltrio have announced their collaboration to bring a fully automated cell culture system to biotherapeutics customers.

RBQM Market Leader, CluePoints, Celebrates Milestone of De-risking 1000 Clinical Studies

RBQM Market Leader, CluePoints, Celebrates Milestone of De-risking 1000 Clinical Studies Risk-Based Quality Management: 10 Years of enhancing Quality, Accuracy, and Integrity across all Clinical Trial Data

Verisense Health Introduces Eminent New Board of Advisors

Verisense® Health, Inc., a digital health software and data management company, today announced the four founding members of its Board of Advisors – Dr. William Crown, Paul Hartung, Dr. Ronald C. Kessler, and Josh Tolkoff. They bring large-scale medical research, statistical, epidemiological, operational and funding expertise to the company.

Creative Enzymes Introduces Two Enzyme Engineering Methods to Accelerate Related Research

Kidney and Pancreas Function Diagnostic Enzymes Are Now Available at Creative Enzymes

TransCure bioServices offers BioVolume 3D imaging for insightful preclinical oncology research

TransCure bioServices adds BioVolume 3D imaging to its service offerings, enabling them to deliver even higher quality tumor growth results to customers.